{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T01:19:04Z","timestamp":1793582344268,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":613,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1093\/annonc\/mdx773","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T20:14:23Z","timestamp":1513196063000},"page":"646-653","source":"Crossref","is-referenced-by-count":212,"title":["Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study"],"prefix":"10.1016","volume":"29","author":[{"given":"S.M.","family":"Swain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Verrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Colomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.L.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Douthwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Waldron-Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kiermaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Eng-Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"31","key":"10.1093\/annonc\/mdx773_bb0010","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdx773_bb0015","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1093\/annonc\/mdx773_bb0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1093\/annonc\/mdx773_bb0025","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1093\/annonc\/mdx773_bb0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdx773_bb0035","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdx773_bb0040","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial","volume":"17","author":"Untch","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdx773_bb0045","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdx773_bb0050","article-title":"Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA)","volume":"77","author":"Schneeweiss","year":"2017","journal-title":"Cancer Res"},{"issue":"14","key":"10.1093\/annonc\/mdx773_bb0055","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1093\/annonc\/mdx773_bb0060","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1093\/annonc\/mdx773_bb0065","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2009.23.6950","volume":"28","author":"Russell","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdx773_bb0070","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdx773_bb0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10549-014-3163-8","article-title":"Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples","volume":"148","author":"Wilson","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdx773_bb0080","article-title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent\/metastatic breast cancer (PERUSE)","volume":"77","author":"Bachelot","year":"2017","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdx773_bb0085","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.2016.34.15_suppl.500","article-title":"Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE)","volume":"34","author":"Hurvitz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9712","key":"10.1093\/annonc\/mdx773_bb0090","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1093\/annonc\/mdx773_bb0095","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","article-title":"Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study","volume":"28","author":"Untch","year":"2010","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1093\/annonc\/mdx773_bb0100","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups","volume":"29","author":"Untch","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9816","key":"10.1093\/annonc\/mdx773_bb0105","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"Baselga","year":"2012","journal-title":"Lancet"},{"issue":"16","key":"10.1093\/annonc\/mdx773_bb0110","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1200\/JCO.2011.39.0823","article-title":"Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study","volume":"30","author":"Guarneri","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdx773_bb0115","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","article-title":"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial","volume":"13","author":"Ismael","year":"2012","journal-title":"Lancet Oncol"},{"issue":"24 Suppl","key":"10.1093\/annonc\/mdx773_bb0120","volume":"73","author":"Hurvitz","year":"2013","journal-title":"Cancer Res"},{"issue":"14","key":"10.1093\/annonc\/mdx773_bb0125","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1200\/JCO.2012.44.8027","article-title":"Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006","volume":"31","author":"Rimawi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdx773_bb0130","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S1470-2045(13)70411-X","article-title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial","volume":"14","author":"Robidoux","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdx773_bb0135","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/bjc.2013.831","article-title":"Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM\/2006-14 trial","volume":"110","author":"Alba","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdx773_bb0140","doi-asserted-by":"crossref","unstructured":"M Buxton, AM DeMichele, S Chia. Efficacy of pertuzumab\/trastuzumab\/paclitaxel over standard trastuzumab\/paclitaxel therapy for HER2+ breast cancer: results from the neoadjuvant I-SPY 2 TRIAL. In Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA, April 16-20, 2016. Abstract CT106. Philadelphia.","DOI":"10.1158\/1538-7445.AM2016-CT106"},{"issue":"6","key":"10.1093\/annonc\/mdx773_bb0145","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2015.62.1268","article-title":"Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized Phase III trial of paclitaxel plus trastuzumab with or without lapatinib","volume":"34","author":"Carey","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdx773_bb0150","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1200\/JCO.2016.34.15_suppl.518","article-title":"Final analysis of WSG-ADAPT HER2+\/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab \u00b1 weekly paclitaxel in HER2+\/HR- early breast cancer (EBC)","volume":"34","author":"Nitz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdx773_bb0155","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","article-title":"HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial","volume":"18","author":"Llombart-Cussac","year":"2017","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdx773_bb0160","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"issue":"2","key":"10.1093\/annonc\/mdx773_bb0165","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"Von Minckwitz","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341935495X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341935495X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/3\/646\/24530834\/mdx773.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:53:21Z","timestamp":1624697601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341935495X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S092375341935495X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx773","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}